Abstract Submission

Abstract Submission

Late Abstract Submission is now closed.

Deadline was: Monday, 17 August, 2020 at 23:59 Central European Summer Time


Instrucciones en Español

Instruções em Português

View the  Abstract Topics


Abstract Notifications from 1st submission Sent 
Late Abstract Submission Deadline 

Monday, 17 August , 2020, 23:59 CET  

Late Abstract Submission Notification*  by September 30, 2020



Please read the submission rules before submitting an abstract. 

  • Abstracts must be submitted online via the website only.  ABSTRACTS SUBMITTED BY EMAIL WILL NOT BE ACCEPTED. 
  • Presentation Type: Abstracts may be submitted for oral or e-poster presentation or both. The Scientific Committee will determine whether the abstract will be accepted for presentation, with consideration given to the author’s preference. 
  • Abstracts must be received by the announced deadline. Abstracts received after the deadline will not be considered.  
  • One person may serve as presenting author on a maximum of 3 abstracts.
  •  Presenting authors must be registered participants. Only abstracts of authors who have paid their registration fees by September 1, 2020 will be scheduled for presentation and included for publication. 
  • Submission of an abstract acknowledges your acceptance for the abstract to be published in the official congress publications.   
  • The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract. 
  • All accepted abstracts will be published in the peer-reviewed journal PCCM, Pediatric Critical Care Medicine. 
  • Disclosure of Conflicts of Interest: Abstract submitters will be required to disclose any conflict of interests in the submission form.
    • Abstracts submitted by those who are within 3 years of completing their most recent training program (e.g. MSN, Ph.D., MD, Residency, Fellowship) are eligible for the Early Investigator award. Within the abstract submission system, you will be asked to indicate if you are eligible for this award and wish to be considered. Awards are selected on accumulated scores of both abstract and presentation.
    • Abstracts submitted by those who graduated more than 3 years ago are eligible for the Established Investigator award. Within the abstract submission system, you will be asked to indicate if you are eligible for this award and wish to be considered. Awards will selected on accumulated scores of both abstract and presentation.
    • All abstracts must be submitted in clear English with accurate grammar and spelling of a quality suitable for publication. If you need help, please arrange for the review of your abstract by a colleague who is a native English speaker, by a university specific publications office (or other similar facility) or by a copy editor, prior to submission. 
    • Abstracts selected for ePoster Presentation must be uploaded in English.
  • Instructions for preparation of presentations will be made available on the Congress website. 


​Before you begin, please prepare the following information:

  • Presenting author’s contact details:
    • Full first and family name(s)
    • Email address
    • Affiliation details: department, institution / hospital, city, state (if relevant), country
    • Phone number 
  • Author and co-authors’ details  
  • Preferred Presentation type: You can choose to have your abstract considered for both Oral and E-Poster presentation, or for E-Poster presentation only. Oral presentations must be made in English. 
  • Abstract title – must be in UPPER CASE and limited to 25 words. Please submit symbols as words. 
  • Abstract text - limited to 250 words including acknowledgements. 
  • Abstract topic– select the abstract topic per thelist of topics. 
  • Images – The maximum file size of each image is 500 KB. The maximum pixel size of the graph/image is 600(w) x 800(h) pixel. You may upload images in JPG, GIF or PNG format. 
  • Abstracts should clearly state: 
    • Aims & Objectives:
    • Methods:
    • Results:
    • Conclusions:
  • Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears.  
  • Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content. 
  • Submissions may not contain patient names, hospital ID numbers or other identifying information. 
  • The submission form allows you to store your abstract as a DRAFT until the deadline. After the deadline if not submitted, drafts will be deleted. 
  • Click on the Finish Submission button at the end of the process in order to submit your abstract
  • You will receive an abstract ID number via email after you have submitted your abstract. Please refer to this abstract number in all correspondence regarding the abstract. 
  • Please contact us if you have not received confirmation that your abstract has been submitted. 
  • Please do not submit multiple copies of the same abstract. 


Look at examples! The 2018 PCCM Abstract Supplement from WFPICCS can be found here.

Follow instructions provided on the abstract submission site very closely, including word limits, rules for abbreviations, and images. Your title should be succinct while relaying the overall message of the abstract.

The AMA Manual of Style provides excellent guidance on writing a structured abstract. We have adapted these guidelines below (from Iverson C. Structured abstracts. In: AMA Manual of Style: A Guide for Authors and Editors. New York, NY: Oxford University Press; 2007.)

  • Aims and Objectives: Begin the abstract with a sentence or two explaining the clinical (or other) importance of the study question. State the precise objective or study question addressed in the report. If more than 1 objective is addressed, indicate the main objective and state only key secondary objectives. If an a priori hypothesis was tested, state that hypothesis.
  • Methods: Include all of the following components as applicable:
    • Design: Describe the basic design of the study. State the years of the study and the duration of follow-up. If applicable, include the name of the study (eg, the Framingham Heart Study).
    • Setting and Participants: Describe the study setting, for example, PICU in an academic children’s hospital, rural hospital, etc. State the clinical disorders, important eligibility criteria, and key sociodemographic features of patients. Provide the numbers of participants and how they were selected (see below), including the number of otherwise eligible individuals who were approached but refused. If matching is used for comparison groups, specify the characteristics that are matched. In follow-up studies, indicate the proportion of participants who completed the study. In intervention studies, provide the number of patients withdrawn because of adverse effects. For selection procedures, use these terms, if appropriate: random sample (where random refers to a formal, randomized selection in which all eligible individuals have a fixed and usually equal chance of selection); population-based sample; referred sample; consecutive sample; volunteer sample; convenience sample.
    • Intervention(s): Describe the essential features of any interventions, including their method and duration of administration. Name the intervention by its most common clinical name, and use nonproprietary drug names.
    • Main Outcome Measure(s): Indicate the primary study outcome measurement(s) as planned before data collection began.
  • Results: Provide and quantify the main outcomes of the study, including confidence intervals (eg, 95%) or P For comparative studies, express the differences between groups with confidence intervals. Explain outcomes or measurements unfamiliar to a general medical readership. Declare important measurements not presented in results. As relevant, indicate whether observers were blinded to patient groupings, particularly for subjective measurements. If differences for the major study outcome measure(s) are not significant, state the clinically important difference sought and provide the confidence interval for the difference between the groups. When risk changes or effect sizes are given, indicate absolute values. For studies of screening and diagnostic tests, report sensitivity, specificity, and likelihood ratio. If predictive value or accuracy is given, provide prevalence or pretest likelihood as well. For all randomized controlled trials, include the results of intention-to-treat analysis, and for all surveys include response rates.
  • Conclusions: Provide only conclusions of the study directly supported by the results, taking into account the limitations (eg, observational study, selected population), along with implications for clinical practice, avoiding speculation and overgeneralization. Indicate whether additional study is required before the information should be used in usual clinical settings. Give equal emphasis to positive and negative findings of equal scientific merit.


During abstract submission you will be asked to confirm that you agree to the following: 

  1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after final submission and I am aware that it will be published exactly as submitted.
  2. Submission of the abstract constitutes my consent to publication (e.g. Conference website, programmes, other promotions, etc.)
  3. As the Abstract Submitter, I warrant and represent that I am the sole owner or have the rights of all the information and content (“Content”) provided to WFPICCS 2020 and Kenes Group (Hereafter: “The Organisers”). The publication of the abstract does not infringe any third-party rights including, but not limited to, intellectual property rights.
  4. As the Abstract Submitter, I grant the Organisers a royalty-free, perpetual, irrevocable nonexclusive licence to use, reproduce, publish, translate, distribute, and display the Content.
  5. The Organisers reserve the right to remove from any publication an abstract that does not comply with the above.
  6. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.
  7. I certify that this study included approval of IRB or equivalent for clinical studies or IACUC or equivalent for research involving vertebrate animals.